InflaRx (IFRX) director lists options and 10,000 Ordinary Shares
Rhea-AI Filing Summary
InflaRx N.V. director Anthony S. Gibney filed an initial ownership report showing his equity stake. He holds 10,000 Ordinary Shares directly, plus several stock options over Ordinary Shares with exercise prices between $1.17 and $2.41 per share that expire from 2028 through 2036. Many of these options, granted between 2018 and 2025, are fully vested and exercisable, while a 30,000-share option granted on January 6, 2026 will vest in four equal quarterly installments, subject to continued service.
Positive
- None.
Negative
- None.
Insider Trade Summary
8 transactions reported
Mixed
8 txns
Insider
Gibney Anthony S
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 11,667 shares (Direct);
Ordinary Shares — 10,000 shares (Direct)
Footnotes (1)
- This option was granted on February 7, 2018 and is fully vested and exercisable as of the date hereof. This option was granted on July 2, 2021 and is fully vested and exercisable as of the date hereof. This option was granted on January 12, 2022 and is fully vested and exercisable as of the date hereof. This option was granted on January 24, 2023 and is fully vested and exercisable as of the date hereof. This option was granted on January 5, 2024 and is fully vested and exercisable as of the date hereof. This option was granted on January 3, 2025 and is fully vested and exercisable as of the date hereof. This option was granted on January 6, 2026 and will vest and become exercisable in four equal installments of 7,500 shares on each quarterly anniversary of such grant date, subject to continued service through such dates.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What does InflaRx (IFRX) director Anthony S. Gibney report on this Form 3?
He reports initial ownership of 10,000 Ordinary Shares and multiple stock options. The options cover Ordinary Shares with exercise prices between $1.17 and $2.41, expiring from 2028 through 2036, reflecting his equity-based alignment with InflaRx.
What are the key terms of Anthony S. Gibney’s InflaRx (IFRX) stock options?
His options are rights to buy Ordinary Shares at fixed prices between $1.17 and $2.41. These options have expiration dates ranging from 2028 to 2036, giving him long-dated potential to acquire additional InflaRx equity at those strike prices.
Which of Anthony S. Gibney’s InflaRx (IFRX) options are already vested?
Options granted on February 7, 2018, July 2, 2021, January 12, 2022, January 24, 2023, January 5, 2024, and January 3, 2025 are fully vested and exercisable. This means he can already use these options to purchase Ordinary Shares at their stated exercise prices.
How does the January 6, 2026 InflaRx (IFRX) option grant vest for Anthony S. Gibney?
The option granted on January 6, 2026 for 30,000 underlying Ordinary Shares vests in four equal installments of 7,500 shares. Each installment vests on a quarterly anniversary of the grant date, contingent on his continued service through those vesting dates.
Does this InflaRx (IFRX) Form 3 show any insider buying or selling by Anthony S. Gibney?
It does not show buying or selling transactions; it records his existing holdings. The filing lists his direct ownership of 10,000 Ordinary Shares and his outstanding stock options, many of which are already vested and exercisable, as an initial beneficial ownership statement.